A Study On Biochemical And Haematological Parameters In Acute Respiratory Infection Patients
DOI:
https://doi.org/10.52783/jns.v14.2662Keywords:
Acute respiratory infections, biochemical parameters, Hematological parameters, CBC, AST, and ALTAbstract
Background:Acute respiratory infections (ARI) caused by viruses or bacteria, with an evolution of less than 15 days, and which manifest with symptoms such as cough, nasal congestion and obstruction, sore throat, dysphonia or respiratory distress. The measurement of biochemical parameters provides information about the functional status of major organs. Enzymes are widely used in toxicological studies as markers of detection and evaluation of cell damage. Haematological parameters, including red and white blood cell counts and haemoglobin concentration, are widely used clinical indicators of health and disease. The primary objective of the study is to analyze the Biochemical& Hematological parameters among the acute respiratory infection patients in ACS Medical College and Hospitals.
Method: The Experimental study occurred at the Department of Allied Health Science (AHS) in a private medical college and hospital in Chennai, Tamil Nadu. The study included adolescent people (age >18) with reported acute respiratory infection.
Result: In this study symptomatic patients values are like CBC, AST, and ALT are significantly high and asymptomatic patient’s values are insignificant.
Conclusion: We observed that most of the symptomatic patients of Acute respiratory infection has abnormal CBC (HB, Platelet), LFT (AST, ALT) levels. And also, we test the asymptomatic patients of acute respiratory infection, has normal level of CBC & LFT
Downloads
Metrics
References
Dr. Naresh Dang,Acute Respiratory Infection: Symptoms, causes, treatments, https://www.zotezo.com/conditions/acute-respiratory-infection/ March13,2024
Pablo Letelier , Nicole Encina , Pablo Morales , Alejandra Riffo , Halett Silva , Ismael Riquelme , Neftalí Guzmán Role of biochemical markers in the monitoring of COVID-19 patients. 2021 Mar 12;40(2):115-128. doi: 10.5937/jomb0-29341
Osama Najjar, IFCC Interim Guidelines on Biochemical / Hematological Monitoring of COVID-19 Patients. October 7, 2020 https://doi.org/10.1515/cclm-2020-1414
Erhabor, Muhammad HA, Muhammad K, Onwuchekwa C and Egenti NB, Interpretation of Full Blood Count Parameters in Health and Disease, April 28, 2021. DOI: 10.23880/hij-16000180.
Samir N P Kelada, David L Aylor, Bailey C E Peck , Joseph F Ryan , Urraca Tavarez , Ryan J Buus, Darla R Miller, Elissa J Chesler, David W Threadgill , Gary A Churchill, Fernando Pardo-Manuel de Villena, Francis S Collins, Genetic Analysis of Hematological Parameters in Incipient Lines of the Collaborative Cross, 2012 Feb 1;2(2):157–165. doi: 10.1534/g3.111.001776
Ajobiewe H. F.1, Ajobiewe J. O.2, Nehemiah Edem, Prevalence of Acute Respiratory Tract Infection (ARI) in Paediatric Patient Attending National Hospital Abuja, Nigeria, 2018; 8(7):132-136 doi:10.5923/j.ajmms.20180807.03
www.healthline.com › health › acute-respiratory-diseaseAcute Respiratory Infection: Causes, Symptoms, and Diagnosis ,MARCH 04 2019, https://www.healthline.com/health/acute-respiratory-disease
Purushothama V. Dasaraju, Chien Liu, Samuel Baron, Medical Microbiology. 4th edition. Galveston (TX): University of Texas Medical Branch at Galveston; 1996. Chapter 93.https://pubmed.ncbi.nlm.nih.gov/21413304/
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J et al. A Novel Coronavirus from Patients with Pneumonia in China,. N Eng J Medic. 2019. 2020;382(8):727-33
The species Severe acute respiratory syndromerelated coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5(4):536-44.
Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020;7(1):11.
Yeo C, Kaushal S, Yeo D. Enteric involvement of coronaviruses: is faecal-oral transmission of SARSCoV-2 possible?. Lancet Gastroenterol Hepatol. 2020;5(4):335-7.
Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. N EnglJ Medic. 2020;382(13):1199-207.
Ministry of health and family welfare, Government of India. [Internet] Guidelines on the clinical management of COVID-19. Available at: https://www.mohfw.gov.in/pdf/GuidelinesonClinicalManagementofCOVID1912020.pdf. Accessed on 12 May 2020.
Şimşek yavuz S, Ünal S. Antiviral treatment of COVID-19. Turk J Med Sci. 2020;50(SI-1):6119.
Huang L, Zhang X, Zhang X, Wei Z, Zhang L, Xu J et al. Rapid asymptomatic transmission of COVID-19 during the incubation period demonstrating strong infectivity in a cluster of youngsters aged 16-23 years outside Wuhan and characteristics of young patients with COVID 19: A prospective contact-tracing study. J Infect. 2020;80(6):e1-13.
Richardson S, Hirsch J, Narasimhan M, Crawford J, McGinn T, Davidson K et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. J Am Med Assoc. 2020.
Zhang C, Shi L, Wang F. Liver injury in COVID-19: management and challenges. Lanc GastroenterolHepatol. 2020;5(5):428-30.
Guan W, Ni Z, Hu Y, Liang W, Ou C, He J et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Medic. 2020;382(18):1708-
Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis T, Politou M et al. Hematological findings and complications of COVID-19. Am J Hematol. 2020;
World Health Organization. Clinical management of severe acute respiratory infection when Middle East respiratory syndrome coronavirus (MERS-CoV) infection is suspected: interim guidance. Geneva: World Health Organization; 2019. [cited on Oct 3, 2020]. Available from https://www.who.int/csr/disease/coronavirus_infections/case-management-ipc/en/
Republic of Turkey. Ministry of Health. Guide of coronavirus disease 19. [cited on Oct 3, 2020]. Available from: https://covid19bilgi.saglik.gov.tr/depo/rehberler/coronavirus disease 19-rehberi/COVID19_REHBERI_GENEL_BILGILER_.
Zhou Y, Yang Z, Guo Y, Geng S, Gao S, Ye S, et al. A new predictor of disease severity in patients with COVID-19 in Wuhan, China. medRxiv. 2020.20042119. https://doi.org/10.1101/2020.03.24.20042119
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course andrisk factors for mortality of adult inpatients with COVID-19in Wuhan, China: a retrospective cohort study. Lancet.2020;395(10229):1054-62. https://doi.org/10.1016/S01406736(20)30566-3
Li Y, Zhao K, Wei H, Chen W, Wang W, Jia L, et al. Dynamicrelationship between D-dimer and COVID-19 severity. BrJ Haematol. 2020;190(1): e24-7. https://doi.org/10.1111/bjh.16811
Deng X, Lui B, Li J, Zhang J, Zhao Y, Xu K, et al. Blood biochemical characteristics of patients with coronavirus disease 2019 (COVID-19): a systemic review and meta-analysis. Clin Chem Lab Med. 2020;58(8):1172-81. https://doi.org/10.1515/cclm-2020-0338
Shang W, Dong J, Ren Y, Tian M, Li W, Hu J, et al. The value of clinical parameters in predicting the severity of COVID-19. J Med Virol. 2020;92(10):2188-92. https://doi.org/10.1002/ok
Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J etal. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lanc Infect Diseas. 2020;20(4):425-34.
Young BE, Ong SWX, Kalimuddin S, Low JG, Tan SY, Loh J et al. Epidemiologic Features and Clinical Course of Patients Infected with SARS-CoV-2 in Singapore. J Am Med Assoc. 2020;323(15):1488–94.
Yang AP, Liu JP, Tao WQ, Li HM. The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. Int Immunopharmacol. 2020; 84:106504.
Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;146(1):110-8.
Gautret P, Lagier JC, Parola P, Hoang VT, MeddebL, Sevestre J et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Travel Med Infect Dis. 2020; 34:101663.
Guidance for discharge and ending isolation in the context of widespread community transmission of COVID-19 - first update [Internet]. European Centre for Disease Prevention and Control. 2020. Available at: lhttps://www.ecdc.europa.eu/en/publications-data/covid-19-guidance-discharge-and-ending-isolation. Accessed on 12 May 2020. Cite this article as: Agrawal A, Tyagi P, Mahavar S,
COCKBURN, W. C. &AssAAD, F. Bulletin of theWorld Health Organization, 49: 1-12 (1973).
AssAAD F. & COCKBURN, W. C. Bulletin ofthe WorldHealth Organization, 51: 437-445 (1974).
WHO Chronicle, 30: 271 (1976).
SOBESLAVSK4, 0. ET AL. Bulletin of the World HealthOrganization, 55: 625-632 (1977).
MILLER, D. L. Postgraduate medical journal, 49: 748(1973).
CROFTON J. & DOUGLAS, A. Respiratory diseases,2nd ed. Oxford & Edinburgh, Blackwell, 1975.
WHO Official Records, No. 233, 1976, pp. 63-109.
WORLD HEALTH ORGANIZATION. World health statistics annual, 1972, Vol. 1. Geneva, 1975.
WORLD HEALTH ORGANIZATION. World health statistics annual, 1973-76, Vol. 1. Geneva, 1976.
UN demographic yearbook, 1974.
CHABAUD, D. F. & COULANGE, P. Archives del'Institut Pasteur de Madagascar, 44: 147-166 (1975).
BwIBo, N. 0. Tropical andgeographical medicine, 22:167 (1970).
MILLER, D. L. British medical journal, 2: 75 (1964).
PAN AMECAN HEALTH ORGANIZATION. PAHOScientific Publication No. 262, 1973.
GRYZEVSKAJA, E. V. In: Proceedings of the ScientificSession on Staphylococcal Infections, Leningrad, 6-13December 1967.
HOPE-SIMPSON, R. E. & MILLER, D. L. Postgraduatemedical journal, 49: 763-770 (1973).
ANGELESCU, M. The rational use of antibiotics.Bucharest, EdituraMedicala, 1976, pp. 128-131.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
